19 completed. 19 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 19 |
| Phase 2 | 1 | Completed 1 |
Follow Nematode Infections: new trials by email Literature Review of Nematode Infections trials Research Report on Nematode Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability and PK of Single and Multiple Doses of Oxantel Pamoate Tablets Oxantel Pamoate, Placebo - Healthy | Phase 1 | Completed | Swiss Tropical & Public Health Institute | 45 | 2025-01-27 | 2025-08-28 |
| A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When Given as a New Type of Tablet to Healthy Participants BAY 44-4400 - Soil-transmitted Helminth Infection, Onchocerciasis (River Blindness) | Phase 1 | Completed | Bayer | 14 | 2024-05-07 | 2024-09-27 |
| PK, Safety and Tolerability of Single and Multiple Doses of Oxfendazole Tablets Oxfendazole, Placebo - Filariasis | Phase 1 | Completed | Swiss Tropical & Public Health Institute | 30 | 2022-04-21 | 2022-12-20 |
| A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years Moxidectin - Onchocerciasis | Phase 1 | Completed | Medicines Development for Global Health | 36 | 2021-03-29 | 2025-09-05 |
| Na-GST-1/Alhydrogel With or Without CpG 10104 in Gabonese Adults Na-GST-1, CPG 10104 - Hookworm Infection, Hookworm Disease | Phase 1 | Completed | Baylor College of Medicine | 24 | 2018-02-01 | 2021-01-13 |
| Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside LSF emodepside (BAY 44-4400) or matching placebo - Filariasis | Phase 1 | Completed | Drugs for Neglected Diseases | 24 | 2017-11-14 | 2020-04-15 |
| Relative Bioavailability Study of Emodepside IR-tablets and Solution Emodepside (BAY 44-4400) - Filariasis | Phase 1 | Completed | Drugs for Neglected Diseases | 77 | 2017-10-26 | 2020-03-09 |
| Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children Na-GST-1/Alhydrogel, Na-APR-1 (M74)/Alhydrogel, Hepatitis B Vaccine - Hookworm Disease, Hookworm Infection | Phase 1 | Completed | Baylor College of Medicine | 60 | 2017-01-01 | 2025-01-13 |
| Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE) Ivermectin, Diethylcarbamazine Albendazole (IDA) - Wuchereria Bancrofti Infection | Phase 1 | Completed | University Hospitals Cleveland Medical Center | 66 | 2016-04-17 | 2019-04-26 |
| Study of Na-APR-1 (M74)/Alhydrogel® Co-administered With Na-GST-1/Alhydrogel in Brazilian Adults Na-GST-1/Alhydrogel plus GLA-AF, Na-APR-1 (M74)/Alhydrogel, Na-APR-1 (M74)/Alhydrogel plus GLA-AF - Hookworm Infection, Hookworm Disease | Phase 1 | Completed | Baylor College of Medicine | 60 | 2016-01-01 | 2019-12-03 |
| First in Man Clinical Trial of Emodepside (BAY 44-4400) emodepside (BAY 44-4400), placebo - Healthy Volunteers | Phase 1 | Completed | Drugs for Neglected Diseases | 79 | 2015-12-01 | 2020-04-13 |
| Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults Na-APR-1 (M74)/Alhydrogel®, Na-GST-1/Alhydrogel®, Hepatitis B vaccine - Hookworm Infection, Hookworm Disease | Phase 1 | Completed | Baylor College of Medicine | 32 | 2014-11-01 | 2017-05-31 |
| Safety and Immunogenicity Study of Na-GST-1 With or Without CpG Na-GST-1/Alhydrogel®, CpG 10104 - Hookworm Infection, Hookworm Disease | Phase 1 | Completed | Baylor College of Medicine | 24 | 2014-10-01 | 2025-07-04 |
| Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults Na-APR-1 (M74)/Alhydrogel®, Gluco-Pyranosylphospho-Lipid A Aqueous Formulation - Hookworm Infection, Hookworm Disease | Phase 1 | Completed | Baylor College of Medicine | 40 | 2013-09-01 | 2019-07-31 |
| Desensitising Celiac Disease Patients With the Human Hookworm Necator americanus - Celiac Disease | Phase 1 / Phase 2 | Completed | The Prince Charles Hospital | 12 | 2012-08-01 | 2014-10-20 |
| Impact of Health Education on School Children Health Education package - Intestinal Helminthiasis | Phase 1 | Completed | University of Malaya | 317 | 2012-07-01 | 2014-06-24 |
| Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant 10 μg Na-GST-1/Alhydrogel, 30 μg Na-GST-1/Alhydrogel, 100 μg Na-GST-1/Alhydrogel - Hookworm Infection, Hookworm Disease | Phase 1 | Completed | Baylor College of Medicine | 40 | 2012-05-01 | 2025-01-06 |
| Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With or Without Additional Adjuvant in Brazilian Adults 10 μg Na-GST-1/Alhydrogel, 30 μg Na-GST-1/Alhydrogel, 100 μg Na-GST-1/Alhydrogel - Hookworm Infection, Hookworm Disease | Phase 1 | Completed | Baylor College of Medicine | 102 | 2011-11-01 | 2017-05-31 |
| Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection Na-ASP-2/Alhydrogel Hookworm Vaccine, Saline placebo - Hookworm Infection | Phase 1 | Completed | Baylor College of Medicine | 36 | 2005-04-01 | 2017-05-31 |
Ancylostomiasis (11) · Hookworm Infections (9) · Neglected Diseases (7) · Anemia, Iron-Deficiency (6) · Filariasis (4) · Onchocerciasis (4) · Parasitic Diseases (3) · Celiac Disease (1) · Elephantiasis, Filarial (1) · Health Education (1) · Helminthiasis (1) · Intestinal helminthiasis (1) · Onchocerciasis, Ocular (1) · Secernentea Infections (1)
Infections (19) · Helminthiasis (18) · Secernentea Infections (17) · Parasitic Diseases (16) · Strongylida Infections (11) · Disease Attributes (7) · Hemic and Lymphatic Diseases (7) · Metabolic Diseases (7) · Nutritional and Metabolic Diseases (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Anemia (6) · Anemia, Hypochromic (6) · Hematologic Diseases (6)
Bay 44-4400 (4) · Hepatitis B Vaccines (2) · emodepside (2) · ASP-1 protein, Necator americanus (1) · CPG-oligonucleotide (1) · D-Worm (1) · GLA-AF adjuvant (1) · Granuflex E (1) · Ivermectin (1) · Praziquantel (1) · moxidectin (1) · oxantel pamoate (1) · oxfendazole (1) · toltrazuril (1)
Baylor College of Medicine (9) · Drugs for Neglected Diseases (3) · Swiss Tropical & Public Health Institute (2) · Bayer (1) · Medicines Development for Global Health (1) · The Prince Charles Hospital (1) · University Hospitals Cleveland Medical Center (1) · University of Malaya (1)
United States (4) · Gabon (3) · United Kingdom (3) · Brazil (2) · Tanzania (2) · Australia (1) · Côte d’Ivoire (1) · Germany (1) · Ghana (1) · Malaysia (1)
David Diemert, MD (4) · Ayola Adegnika, MD (3) · Ahmed K. Al-Delaimy, MSc (1) · Alexander Loukas, PhD (1) · Daniel Paris (1) · Daniel Paris, MD, PhD (1) · David J Diemert, MD (1) · Dianne Jones, BAppSc (1) · Frederic Monnot (1) · Gary Simon, M.D., Ph.D (1) · Hesham M Al-Mekhlafi, PhD (1) · Hussein Mbarak, MD (1) · Jennifer Keiser, PhD (1) · Jeremy Dennison (1) · Jeremy Dennison, PhD MBChB (1)
PMID 28464026, PMID 18396361, PMID 31107869, PMID 32926834, PMID 34310218, PMID 34597297, PMID 37262040, PMID 38513684, PMID 40707999, PMID 41121745, PMID 41662151, PMID 41705834, PMID 42848323
2017 (2), 2015 (1), 2023 (1)